Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | PAM | P19021 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12836795 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL2508512 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL6041032 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL828637 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL18218758 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL11127403 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL4749529 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL15799168 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL1361856 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA | |
| SCHEMBL337170 | 1.00 | KMT2A (0.54) | KMT2ASMN1; SMN2DGKAPRKCALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111217791-B | Ibrutin intermediate and preparation method thereof | 广东东阳光药业股份有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115014886-A | Method for preparing measurement sample, method for analyzing measurement sample, reagent, and kit | 希森美康株式会社 | 2022-09-06 | — | — | CN | claimed |
| CN-111217791-A | Ibrustat intermediate and preparation method thereof | 广东东阳光药业有限公司 | 2020-06-02 | — | — | CN | claimed |
| CN-110878079-A | Preparation method of high-purity eliagliptat | 北京启慧生物医药有限公司 | 2020-03-13 | — | — | CN | claimed |
| WO-2020004535-A1 | SENSOR CHIP FOR HIGH-SENSITIVITY DETECTION OF CELLS, ETC. | 株式会社堀場製作所 | 2020-01-02 | — | — | WO | claimed |
| EP-0712862-B1 | Selective acylation of epsilon-amino groups in insulin | LILLY CO ELI (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1227107-A1 | Selective acylation of E-amino groups | ELI LILLY AND COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| WO-1996015803-A1 | SELECTIVE ACYLATION OF ε-AMINO GROUPS | ELI LILLY AND COMPANY (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0712862-A2 | Selective acylation of epsilon-amino groups | ELI LILLY AND COMPANY (US) | 1996-05-22 | — | — | EP | claimed |
| EP-4702004-A1 | NONIONIC SURFACTANTS | Detect, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| CN-119548644-A | Pharmaceutical composition and preparation method and application thereof | 四川大学 | 2025-03-04 | — | — | CN | disclosed |
| US-20240360076-A1 | NONIONIC SURFACTANTS | DETECT INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-111217791-B | Ibrutin intermediate and preparation method thereof | 广东东阳光药业股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4252846-A1 | REGULATOR FOR EXPRESSION AND/OR FUNCTION OF RPS25 GENE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| WO-1999043706-A1 | DERIVATIVES OF GLP-1 ANALOGS | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043341-A1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043708-A1 | GLP-1 DERIVATIVES OF GLP-1 AND EXENDIN WITH PROTRACTED PROFILE OF ACTION | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| EP-0839902-A2 | Microcapsules containig bleaching aids | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-06 | — | — | EP | disclosed |
| US-5426190-A | Preparation of N-(organocarbonyloxy)-succinimide derivatives of N-hydroxysuccinimide | PPG INDUSTRIES, INC. (US) | 1995-06-20 | — | — | US | disclosed |
| US-4126628-A | BASIC CATALYST | CANADIAN PATENTS AND DEVELOPMENT LIMITED (CA) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360076-A1 | NONIONIC SURFACTANTS | POLL, POLRMT, POLI | KMT2A 3615/4885SMN1; SMN2 1112/4885DGKA 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.